Boston Scientific Corp Cash Flow Conversion Efficiency
Boston Scientific Corp cash flow conversion efficiency. Based on the latest financial reports, Boston Scientific Corp (BSX) has a cash flow conversion efficiency ratio of 0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($348.00 Million) by net assets ($26.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Boston Scientific Corp stock valuation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Boston Scientific Corp (1991–2025)
Cash flow conversion efficiency of Boston Scientific Corp from 1991 to 2025. This chart illustrates how Boston Scientific Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BSX stock price and chart for real-time trading data and today's change.
Boston Scientific Corp Cash Flow Conversion Ratio Explained
Boston Scientific Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Boston Scientific Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boston Scientific Corp ranked by their cash flow conversion efficiency. Review Boston Scientific Corp (BSX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Macquarie Group Ltd
AU:MQG
|
0.087x |
|
Natwest Group PLC
NYSE:NWG
|
0.161x |
|
NETEASE INC. O.N.
F:4Y01
|
0.081x |
|
ESSILORLUXOTTICA 1/2/O.N.
F:ESLC
|
N/A |
|
Barclays PLC
F:BCY2
|
N/A |
|
Atlas Copco AB Series A
ST:ATCO-A
|
0.047x |
|
Energy Transfer LP
NYSE:ET
|
0.038x |
|
TC Energy Corp
TO:TRP
|
0.070x |
Annual Cash Flow Conversion Efficiency for Boston Scientific Corp (1991–2025)
The table below shows the annual cash flow conversion efficiency of Boston Scientific Corp from 1991 to 2025. Also see BSX current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.47 Billion | $4.53 Billion | 0.185x | +18.68% |
| 2024-12-31 | $22.00 Billion | $3.44 Billion | 0.156x | +21.81% |
| 2023-12-31 | $19.53 Billion | $2.50 Billion | 0.128x | +47.60% |
| 2022-12-31 | $17.57 Billion | $1.53 Billion | 0.087x | -22.81% |
| 2021-12-31 | $16.62 Billion | $1.87 Billion | 0.112x | +14.34% |
| 2020-12-31 | $15.33 Billion | $1.51 Billion | 0.098x | -25.64% |
| 2019-12-31 | $13.88 Billion | $1.84 Billion | 0.132x | +272.38% |
| 2018-12-31 | $8.72 Billion | $310.00 Million | 0.036x | -82.53% |
| 2017-12-31 | $7.01 Billion | $1.43 Billion | 0.203x | +40.89% |
| 2016-12-31 | $6.73 Billion | $972.00 Million | 0.144x | +52.06% |
| 2015-12-31 | $6.32 Billion | $600.00 Million | 0.095x | -48.81% |
| 2014-12-31 | $6.84 Billion | $1.27 Billion | 0.185x | +12.07% |
| 2013-12-31 | $6.54 Billion | $1.08 Billion | 0.165x | -9.78% |
| 2012-12-31 | $6.87 Billion | $1.26 Billion | 0.183x | +106.57% |
| 2011-12-31 | $11.35 Billion | $1.01 Billion | 0.089x | +208.60% |
| 2010-12-31 | $11.30 Billion | $325.00 Million | 0.029x | -57.61% |
| 2009-12-31 | $12.30 Billion | $835.00 Million | 0.068x | -26.66% |
| 2008-12-31 | $13.14 Billion | $1.22 Billion | 0.093x | +49.61% |
| 2007-12-31 | $15.10 Billion | $934.00 Million | 0.062x | -48.70% |
| 2006-12-31 | $15.30 Billion | $1.84 Billion | 0.121x | -42.81% |
| 2005-12-31 | $4.28 Billion | $903.00 Million | 0.211x | -52.95% |
| 2004-12-31 | $4.03 Billion | $1.80 Billion | 0.448x | +62.99% |
| 2003-12-31 | $2.86 Billion | $787.00 Million | 0.275x | -7.83% |
| 2002-12-31 | $2.47 Billion | $736.00 Million | 0.298x | +22.68% |
| 2001-12-31 | $2.02 Billion | $490.00 Million | 0.243x | -36.33% |
| 2000-12-31 | $1.94 Billion | $739.00 Million | 0.382x | -9.43% |
| 1999-12-31 | $1.72 Billion | $727.00 Million | 0.422x | +33.95% |
| 1998-12-31 | $821.10 Million | $258.50 Million | 0.315x | +285.69% |
| 1997-12-31 | $986.20 Million | $80.50 Million | 0.082x | -44.31% |
| 1996-12-31 | $916.30 Million | $134.30 Million | 0.147x | +341.46% |
| 1995-12-31 | $753.00 Million | $25.00 Million | 0.033x | -83.35% |
| 1994-12-31 | $340.00 Million | $67.80 Million | 0.199x | -25.24% |
| 1993-12-31 | $246.70 Million | $65.80 Million | 0.267x | +56.33% |
| 1992-12-31 | $249.10 Million | $42.50 Million | 0.171x | -47.95% |
| 1991-12-31 | $90.30 Million | $29.60 Million | 0.328x | -- |
About Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyG… Read more